Saturday, July 5, 2025

Latest

PharmaCielo Struggles To Complete Financing, Extends Closing To March

It appears that PharmaCielo (TSXV: PCLO) is having a difficult time raising funds for its operations. The firm this morning announced further delays to the final closing of a financing announced in December.

The company is currently looking to raise $15.0 million from the sale of debenture units in a non-brokered offering. The units bear interest at a rate of 11% per annum, are valid for three years, and contain 250 common share purchase warrants. Warrants are valid for a period of 36 months, and contain a maturity of 50% over the offering price at the time of the initial closing. Debt under the offering is secured by the assets of the company.

Originally estimating to sell 15,000 units at $1,000 per each, the firm expected to close the offering on December 30, with proceeds being used for operations, working capital, and the build-out of its dry flower sales program.

However, the firm managed to close just $5.0 million in gross proceeds on December 31, which included a portion of insider participation.

The remaining portion of the financing however is now not expected to close until March 4, pending ongoing discussions with certain parties.

PharmaCielo last traded at $1.07 on the TSX Venture.


Information for this briefing was found via Sedar and the companies mentioned. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Torex Gold Acquires Reyna Silver For CASH!

Dundee Acquires Adriatic Metals: The Balkan Growth Strategy

Gold Drilling Scaled to 60,000 Meters: How Big Can This Get? | Roger Rosmus – Goliath Resources

Recommended

Antimony Resources Drills 4.17% Antimony Over 7.4 Metres At Bald Hill

ESGold To Expand Mine Building At Montauban In Advance Of Gold & Silver Production

Related News

PharmaCielo Sees Marc Lustig Appointed As Lead Director, Conducts $10 Million Financing

It appears that PharmaCielo Ltd (TSXV: PCLO) has effectively locked in a new lead director....

Tuesday, November 3, 2020, 08:45:53 AM

Pharmacielo Latest Target of Hindenburg Research

Pharmacielo Ltd (TSXV: PCLO) is the latest target of short sellers Hindenburg Research, with Hindenburg...

Monday, March 2, 2020, 09:39:09 AM

Khiron Receives National Strategic Project Status From Colombian Government

This morning Khiron Life Sciences Corp (TSXV: KHRN) announced they received the status of National...

Tuesday, September 22, 2020, 09:43:55 AM

PharmaCielo Looks To Raise $15.0 Million Via 11% Secured Debentures

PharmaCielo (TSXV: PCLO) is returning to the trough for more investor dollars. The firm this...

Wednesday, December 22, 2021, 08:14:04 AM

PharmaCielo Enters Supply Agreement With Xphyto Therapeutics

PharmaCieolo Ltd. (TSXV: PCLO) has announced a supply agreement with Xphyto Therapeutics Corp (CSE: XPHY)....

Monday, January 27, 2020, 11:04:28 AM